ADCs: Key market research findings
- Emergence of targeted and combination therapies
- Growing usage of IgG antibodies
Technavio has released a new market research report on the global ADCs market, which is expected to generated revenues of $7 billion between 2016 and 2020. Individuals detected with cancer are preferring antibody-drug conjugates (ADCs) than other mAbs and chemotherapy, owing to their effectiveness. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue. The market is expected to witness the entry of new molecules such as trastuzumab, glembatumumab vedotin, and inotuzumab ozogamicin. The Americas occupy around 50% of the global ADCs market, owing to the increasing incidences and prevalence of cancer in the US.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments.
“One of the latest trends upcoming in this market is the emergence of targeted and combination therapies. Targeted therapies have fewer adverse effects than conventional non-targeted therapies as targeted therapies exploit the surface markers of infected cells, which are absent or in lower amounts in normal cells. Targeting multiple pathways with ADC in diseases such as cancer reduces the risk of developing treatment-resistant disorders, thereby aiding in the growth of this market in the predicted period,” says Barath Palada, Lead Analyst, Pharma, Technavio Research
IgG is an antibody composed of four peptide chains and helps control the infection of tissues by binding to the pathogen such as virus, bacteria, and fungi. Moreover, these antibodies play an important role in intracellular antibody-mediated proteolysis and antibody dependent cell mediated toxicity. IgG1 find extensive applications in immunotherapy and drug development, thereby propelling the growth prospects of the ADCs market.
The key vendors in the global ADCs market include F. Hoffmann-La Roche, Seattle Genetics, and Takeda Pharmaceuticals. This market is highly competitive due to the presence of only three major providers in the market. The entry of new vendors is likely to intensify the competition, both in terms of innovation and technology in the forecast period. The competitive environment is expected to increase in due to the product extensions, new products, and new applications of the products and services provided.
A more detailed analysis is available in the Technavio report, Global ADCs Market 2016-2020
We can customize reports by other regions and specific segments upon request.
Other related reports:
